Clinical Trials for Pancreas Cancer

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic solid tumors that have progressed after standard therapies, enrolled in tumor-specific refractory cohorts (e.g., melanoma post–PD-(L)1, SCCHN post platinum/PD-(L)1, HER2-negative gastric/GEJ, HGS ovarian, cervical, endometrial, urothelial, ESCC, pancreatic, mCRPC, nonsquamous NSCLC without drivers, and HR+/HER2– breast cancer after CDK4/6 and chemo). Single-arm therapy is patritumab deruxtecan (HER3-DXd) 5.6 mg/kg IV q3w, an HER3-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor (DXd).

ClinicalTrials.gov ID: NCT06172478

Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced solid tumors after ≥1 prior therapy, enriched for ARID1A-altered cancers, ATM-deficient tumors (including mCRPC), and a post–checkpoint inhibitor endometrial cancer cohort; measurable disease required. Patients receive the ATR inhibitor ceralasertib (monotherapy for BAF250a-negative ARID1A or ATM-loss, ceralasertib + PARP inhibitor olaparib for BAF250a-positive ARID1A, or ceralasertib + anti–PD-L1 durvalumab for endometrial), leveraging DNA damage response targeting and potential synergy with PARP inhibition or immunotherapy.

ClinicalTrials.gov ID: NCT03682289

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults and children with biopsy-proven EBV-positive PTLD after solid organ or allogeneic HCT who have failed rituximab (± chemotherapy for SOT) receive tabelecleucel, an allogeneic, off‑the‑shelf EBV‑specific cytotoxic T‑cell therapy matched by HLA and infused on days 1, 8, and 15 of 35‑day cycles. Excludes T‑cell lymphomas, active/untreated CNS PTLD, significant GVHD, recent checkpoint inhibitors or EBV‑directed cell therapies, and requires measurable FDG‑avid disease and adequate organ function.

ClinicalTrials.gov ID: NCT03394365

A Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naïve, Metastatic Pancreatic Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Treatment-naïve adults with metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) receive modified FOLFIRINOX plus nivolumab with NC410, a recombinant LAIR-2–IgG1 Fc fusion protein that binds tumor collagen to block LAIR-1 inhibitory signaling and enhance T-cell activity; a second cohort adds ipilimumab. Excludes prior ICI/PDAC therapy and significant autoimmune/immunosuppression, with efficacy and safety endpoints including ORR, PFS, and toxicity.

ClinicalTrials.gov ID: NCT06941857

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Previously untreated adults with metastatic pancreatic ductal adenocarcinoma (ECOG 0–1) are randomized to gemcitabine/nab-paclitaxel plus SBP-101 (ivospemin) versus placebo; SBP-101 is a polyamine analogue that modulates polyamine metabolism (inhibits ODC1 and S-adenosylmethionine decarboxylase) with preferential pancreatic uptake. Key exclusions include prior systemic therapy for metastasis, BRCA1/2 mutation if known, metformin use, retinopathy risk, active infections, and significant cardiopulmonary comorbidity.

ClinicalTrials.gov ID: NCT05254171

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with inoperable, advanced, well-differentiated (G1–2) SSTR-positive GEP-NETs that progressed after prior 177Lu-SSA PRRT (with ≥6 months disease control) are randomized to RYZ101 (225Ac-DOTATATE, an SSTR2-targeted alpha-emitting radiopharmaceutical) versus investigator’s choice of everolimus, sunitinib, octreotide, or lanreotide. Key eligibility includes Krenning 3–4 on SSTR-PET, ECOG 0–2, and adequate organ function; excludes prior non–Lu-177 PRRT, radioembolization, significant cardiovascular disease, and cirrhosis.

ClinicalTrials.gov ID: NCT05477576

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN18.2-positive advanced solid tumors—specifically gastric/GEJ adenocarcinoma (post up to two lines), untreated metastatic pancreatic ductal adenocarcinoma, and previously treated biliary tract cancer—are enrolled to receive the CLDN18.2-targeted antibody–drug conjugate AZD0901 (sonesitatug vedotin, MMAE payload) as monotherapy or combined with standard pancreatic chemotherapy backbones. Suitable for ECOG 0–1 patients without prior MMAE-ADC or CLDN18.2 therapy (except mAbs) and without significant GI bleeding, ILD/pneumonitis, CNS mets, or grade ≥2 neuropathy.

ClinicalTrials.gov ID: NCT06219941

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic pancreatic adenocarcinoma progressing on gemcitabine (ECOG 0–1, limited comorbidities, adequate organ function) are randomized to glufosfamide 4500 mg/m2 IV q21d versus weekly bolus 5‑FU. Glufosfamide is an investigational oxazaphosphorine alkylating prodrug linked to glucose to enhance tumor uptake via GLUTs, releasing isophosphoramide mustard to form DNA crosslinks; key risks include renal tubular toxicity and myelosuppression.

ClinicalTrials.gov ID: NCT01954992

A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, unresectable or metastatic pancreatic ductal adenocarcinoma (ECOG 0–1, RECIST-measurable) are randomized to mFOLFIRINOX with or without OT-101, an intravenous antisense oligonucleotide that downregulates TGF-β2 to counter tumor immune evasion and metastasis. Primary endpoint is overall survival, with key secondary endpoints of PFS and ORR.

ClinicalTrials.gov ID: NCT06079346

IGNITE: A Phase 2 Study of Maintenance Combinatorial Myeloid Immunotherapy in Patients With Unresectable Pancreatic Ductal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable PDAC (metastatic or locally advanced) who have completed 16–24 weeks of first-line chemotherapy with no progression (stable disease or partial response), ECOG 0–1, measurable disease, and willingness for paired tumor biopsies. Patients receive maintenance IV odetiglucan (soluble β-glucan innate/myeloid immune activator engaging complement/CR3 pathways) plus IV mitazalimab (agonistic anti-CD40 antibody to activate APCs and promote T-cell priming/macrophage reprogramming), with primary efficacy focused on metastatic patients with partial response after induction chemotherapy.

ClinicalTrials.gov ID: NCT07199764